An observational study in Prostatic Neoplasms, Castration-Resistant, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 115 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is one of 6 that started in 2026, is one of 6 observational ones, reaches primary completion later than 6 of the 23 other live ones, and was the 48th registered.
86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:
Coherus Oncology, Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–100 · Men only
Flare Therapeutics Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
T.O.A.D. Oncology SA · Sites in United States, Australia, Canada and 2 more countries
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 115 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 21 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,067 is above the median of 432 across 16 observational studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 82 across the 43 interventional studies, 1,908 across the 6 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07697989Novartis PharmaceuticalsPluvicto Real-world Investigation in Survival in Metastatic CRPC | 2027-01-31 |
| NCT07677254Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | 2027-05-31 |
| NCT07677267Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | 2027-05-31 |
| NCT05519449Janux TherapeuticsStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Adult male patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in the PRECISION data platform.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Adult patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in PRECISION.
A subgroup of the Overall mCRPC Cohort. Patients with evidence of progression on or after 177Lu-PSMA-617 treatment.
A subgroup of the Overall mCRPC Cohort. Patients who initiate ≥1 post-index systemic therapy.
Number of Patients by Number of Lines of Therapy (LOTs) Between mCRPC Diagnosis and Index Date
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Time frame: Baseline
Number of Patients by Number and Type of Prior Therapies Indicated for Advanced Prostate Cancer (PC)
Number of patients by number and type of prior ARPI, taxane, 177Lu-PSMA-617, and other therapies indicated for advanced PC.
Time frame: Baseline
Number of Patients by Number of Prostate-specific Membrane Antigen (PSMA) Scans
Time frame: Baseline up to approximately 5 years
Number of Patients by Timing of PSMA Scans
Timing of scans is categorized as pre-mCRPC diagnosis, post-mCRPC diagnosis but pre-index date, and post-index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Time frame: Baseline up to approximately 5 years
Number of Patients by Number of Post-index LOTs
Time frame: Up to approximately 5 years
Number of Patients by Type of Therapy at Each Post-index LOT
Time frame: Up to approximately 5 years
Time From Index Date to Next Therapy Initiation
The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Time frame: Up to approximately 5 years
Number of Patients by Patient Characteristics
Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.
Time frame: Baseline
Age
Time frame: Baseline
Progression-free Survival (PFS) From Index Date
Time from the applicable index date until progression or death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Time frame: Up to approximately 5 years
PFS From Initiation of First Post-index Therapy, in Patients With ≥1 Post-index Therapy
Time from the initiation of first post-index therapy until progression or death from any cause.
Time frame: Up to approximately 5 years
Overall Survival (OS) From Index Date
Time from the applicable index date until death from any cause. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
Time frame: Up to approximately 5 years
OS From Initiation of First Post-index Therapy, in Those With ≥1 Post-index Therapy
Time from initiation of first post-index therapy until death from any cause.
Time frame: Up to approximately 5 years
Among Patients With ≥1 Post-index Therapy, Number of Patients With a Reduction in PSA Level
Reduction in PSA level categorized as follows: * ≥50% (PSA50) reduction in PSA level * ≥80% (PSA80) reduction in PSA level * ≥90% (PSA90) reduction in PSA level
Time frame: Up to approximately 5 years
Among Patients With ≥1 Post-index Therapy, Number of Patients With PSA <0.2 ng/mL on First Post-index Therapy
Time frame: Up to approximately 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Nov 2026 → May 2027 and completion Nov 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prostatic Neoplasms, Castration-Resistant →